OmniAb (OABI) Competitors

OmniAb has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

OmniAb has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Maravai LifeSciences has a net margin of -37.07% compared to OmniAb's net margin of -115.12%. Maravai LifeSciences' return on equity of -15.70% beat OmniAb's return on equity.

72.1% of OmniAb shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 9.8% of OmniAb shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, OmniAb had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 9 mentions for OmniAb and 7 mentions for Maravai LifeSciences. OmniAb's average media sentiment score of 0.59 beat Maravai LifeSciences' score of 0.58 indicating that OmniAb is being referred to more favorably in the media.

OmniAb presently has a consensus price target of $11.50, suggesting a potential upside of 146.78%. Maravai LifeSciences has a consensus price target of $7.38, suggesting a potential upside of 2.29%. Given OmniAb's higher possible upside, equities research analysts plainly believe OmniAb is more favorable than Maravai LifeSciences.

BioLife Solutions has a net margin of 53.29% compared to OmniAb's net margin of -115.12%. BioLife Solutions' return on equity of 2.70% beat OmniAb's return on equity.

BioLife Solutions has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

OmniAb has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market.

OmniAb presently has a consensus target price of $11.50, suggesting a potential upside of 146.78%. BioLife Solutions has a consensus target price of $31.38, suggesting a potential downside of 18.74%. Given OmniAb's stronger consensus rating and higher probable upside, equities research analysts plainly believe OmniAb is more favorable than BioLife Solutions.

In the previous week, OmniAb had 3 more articles in the media than BioLife Solutions. MarketBeat recorded 9 mentions for OmniAb and 6 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.75 beat OmniAb's score of 0.59 indicating that BioLife Solutions is being referred to more favorably in the news media.

72.1% of OmniAb shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 9.8% of OmniAb shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Fortrea has a net margin of -3.18% compared to OmniAb's net margin of -115.12%. Fortrea's return on equity of 10.72% beat OmniAb's return on equity.

OmniAb has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

72.1% of OmniAb shares are held by institutional investors. 0.7% of Fortrea shares are held by insiders. Comparatively, 9.8% of OmniAb shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Fortrea currently has a consensus price target of $22.10, indicating a potential upside of 8.49%. OmniAb has a consensus price target of $11.50, indicating a potential upside of 146.78%. Given OmniAb's stronger consensus rating and higher probable upside, analysts plainly believe OmniAb is more favorable than Fortrea.

In the previous week, OmniAb had 3 more articles in the media than Fortrea. MarketBeat recorded 9 mentions for OmniAb and 6 mentions for Fortrea. OmniAb's average media sentiment score of 0.59 beat Fortrea's score of 0.41 indicating that OmniAb is being referred to more favorably in the news media.

Fortrea has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

61.9% of Personalis shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 4.2% of Personalis shares are owned by company insiders. Comparatively, 9.8% of OmniAb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Personalis has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

OmniAb has lower revenue, but higher earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

OmniAb has a net margin of -115.12% compared to Personalis' net margin of -153.84%. OmniAb's return on equity of -16.59% beat Personalis' return on equity.

In the previous week, OmniAb had 6 more articles in the media than Personalis. MarketBeat recorded 9 mentions for OmniAb and 3 mentions for Personalis. OmniAb's average media sentiment score of 0.59 beat Personalis' score of 0.38 indicating that OmniAb is being referred to more favorably in the news media.

Personalis presently has a consensus price target of $14.54, indicating a potential downside of 9.49%. OmniAb has a consensus price target of $11.50, indicating a potential upside of 146.78%. Given OmniAb's stronger consensus rating and higher probable upside, analysts plainly believe OmniAb is more favorable than Personalis.